Lorlatinib is the preferred first-line treatment for advanced anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer (NSCLC) based on the 5-year CROWN update.
However, the effects of lorlatinib on the fetus and neonate remain unknown.
